These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23637051)

  • 1. The palatability and tolerability of deferasirox taken with different beverages or foods.
    Goldberg SL; Giardina PJ; Chirnomas D; Esposito J; Paley C; Vichinsky E
    Pediatr Blood Cancer; 2013 Sep; 60(9):1507-12. PubMed ID: 23637051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
    Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
    Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
    Vichinsky E; El-Beshlawy A; Al Zoebie A; Kamdem A; Koussa S; Chotsampancharoen T; Bruederle A; Gilotti G; Han J; Elalfy M
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28296163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
    Galanello R; Piga A; Cappellini MD; Forni GL; Zappu A; Origa R; Dutreix C; Belleli R; Ford JM; Rivière GJ; Balez S; Alberti D; Séchaud R
    J Clin Pharmacol; 2008 Apr; 48(4):428-35. PubMed ID: 18281442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox therapy in children with Fanconi aplastic anemia.
    Tunç B; Tavil B; Karakurt N; Yarali N; Azik FM; Kara A; Culha V; Ozkasap S
    J Pediatr Hematol Oncol; 2012 May; 34(4):247-51. PubMed ID: 22510772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.
    Séchaud R; Dutreix C; Balez S; Pommier F; Dumortier T; Morisson S; Brun E
    Int J Clin Pharmacol Ther; 2008 Feb; 46(2):102-8. PubMed ID: 18218291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
    Ktena YP; Athanasiadou A; Lambrou G; Adamaki M; Moschovi M
    J Pediatr Hematol Oncol; 2013 Aug; 35(6):447-50. PubMed ID: 23669734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of deferasirox.
    Cappellini MD
    Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
    Messa E; Cilloni D; Messa F; Arruga F; Roetto A; Saglio G
    Acta Haematol; 2008; 120(2):70-4. PubMed ID: 18827475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.